Jump to ContentJump to Main Navigation

Journal of Medical Biochemistry

The Journal of Society of Medical Biochemists of Serbia

4 Issues per year


IMPACT FACTOR 2013: 0.721

SCImago Journal Rank (SJR): 0.241
Source Normalized Impact per Paper (SNIP): 0.493

Open Access
VolumeIssuePage

Issues

Open Access

The Potential of Cardiac Markers to Improve Patient Management

Christian Müller1

Department of Internal Medicine, University Hospital Basel, Basel, Switzerland1

This content is open access.

Citation Information: Journal of Medical Biochemistry. Volume 27, Issue 2, Pages 109–113, ISSN (Online) 1452-8266, ISSN (Print) 1452-8258, DOI: 10.2478/v10011-008-0001-8, May 2008

Publication History

Published Online:
2008-05-30

The Potential of Cardiac Markers to Improve Patient Management

B-type natriuretic peptide (BNP) is a quantitative marker for heart failure. The use of BNP in patients with dyspnea has consistently shown to improve patient management and reduce treatment cost. Additional indications with the potential to improve patient management include treatment monitoring in acute and chronic heart failure, pulmonary embolism, and coronary artery disease.

Potencijal Srčanih Markera Za Unapređenje Lečenja Pacijenata

B-tip natriuretskog peptida (BNP) jeste kvantitativni marker za srčane bolesti. Pokazalo se da upotreba BNP-a kod pacijenata sa dispneom unapređuje lečenje i smanjuje troškove tretmana. Dodatne indikacije koje imaju potencijal da unaprede lečenje pacijenata uključuju praćenje toka lečenja u slučajevima akutnih i hroničnih srčanih bolesti, plućne embolije i koronarne arterijske bolesti.

Keywords: BNP; dyspnea; heart failure; monitoring; cost

Keywords: BNP; dispnea; srčana bolest; praćenje; troškovi

  • Remes J, Miettinen H, Reunanen A, et al. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991; 12: 315-21.

  • Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349-53.

  • Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-9.

  • Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161-7.

  • McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002; 106: 416-22.

  • Fonarow GC, Peacock WF, Phillips CO, et al. Admission β-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure, ADHERE Scientific Advisory Committee and Investigators. J Am Coll Cardiol; 49: 1943-50. Epub 2007 Apr 30. [CrossRef]

  • Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004; 350: 647-54.

  • Moe GW, Howlett J, Januzzi JL, et al. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation 2007; 115: 3103-10. Epub 2007 Jun 4.

  • Breidthardt T, Laule K, Strohmeyer AH, et al. Medical and economic long-term effects of B-type natriuretic peptide testing in patients with acute dyspnea. Clin Chem 2007: 1415-22. Epub 2007 Jun 22. [CrossRef]

  • Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 2004; 43: 635-41.

  • Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003; 107: 1278-83.

  • Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-30.

  • Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007: 1733-9. Epub 2007 Apr 2. [Web of Science] [CrossRef]

  • Morrow DA, de Lemos JA, Sabatine MS, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardio 2003; 41: 1264-72.

  • McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351: 9-13.

  • Christ-Crain M, Breidthardt T, Stolz D, Zobrist K, et al. Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia. J Intern Med 2008 Feb 20 [Epub ahead of print]. [CrossRef]

Comments (0)

Please log in or register to comment.